Team:Linkoping Sweden/Safety


Revision as of 19:15, 30 July 2013 by RichardK (Talk | contribs)

Use this page to answer the questions on the safety page.


1. Would any of your project ideas raise safety issues in terms of:

  • researcher safety
  • public safety
  • environmental safety

In the project the organism E.coli is beeing used with a risk group 2. All the laboratory equipment and chemicals beeing used does not present any risks. Some group members have undergone a laboration security course dealing with common risk factors. Considering theese facts, there is no safety issues regarind researchers, the public or the environment.

2. Do any of the new BioBrick parts (or devices) that you made this year raise safety issues?

There is no safety issues concidering our product. It will be an easy and safe detector of allergens with no risk using it.

3. Is there a local biosafety group, committee, or review board at your institution?

  • If yes, what does your local biosafety group think about your project?
  • If no, which specific biosafety rules or guidelines do you have to consider in your country?

The iGEM Safety Committee is not a substitute for national and local university institional biosafety committees

  1. Does your university have a Biosafety Committee or equivalent? Please provide a link to regulations and local requirements.
  2. Is your project in compliance with national regulations and university requirements?
  3. If you are working with any organisms or parts requiring containment arrangements above BSL 1 or equivalent, have you consulted with your Institutional Biosafety Committee regarding your project?

4. Do you have any other ideas how to deal with safety issues that could be useful for future iGEM competitions? How could parts, devices and systems be made even safer through biosafety engineering?


This is an open-ended space for you to consider and suggest ways of improving safety or safety awareness at iGEM and beyond. Some iGEM teams have offered ideas (and sometimes full projects) to limit gene flow, to create software for screening pathogens, and to reduce reliance on antibiotic resistant markers. Other iGEM projects have discussed concerns that might arise if the project succeeded and became widely used, as commercial product or other means of distribution. Some iGEM projects have discussed risks that might materialize if the knowledge generated or methods developed were to become more widely available.